PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation

International trade policy plays a critical role in ensuring that the U.S. biopharmaceutical industry can continue to develop and provide both American and international patients with access to innovative, life-saving medicines. Unfortunately, in many countries across the world, a host of trade barriers, discriminatory measures and the failure to comply with international commitments impedes – or even prevents – this access.

Source: The Catalyst - November 8, 2019 Category: Pharmaceuticals Authors: Douglas Petersen Tags: Research and Development trade Research and Investment Source Type: news